Omotola Watkins, Author at Clinical Trials Portal

MK2870-012

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer

BNT327-02

Safety and preliminary effectiveness of BNT327, an investigational therapy for breast cancer, when given in combination with chemotherapy

Tropion 05

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator’s Choice of Chemotherapy in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

NSABP B-64

EXActDNA-003 / NSABP B-64:Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

NRG-GI008

Using cancer cells in the blood (ctDNA) to determine the type of chemotherapy that will benefit patients who have had surgery for colon cancer

NRG-CC011

COGNITIVE TRAINING FOR CANCER RELATED COGNITIVE IMPAIRMENT IN BREAST CANCER SURVIVORS: A MULTI-CENTER RANDOMIZED DOUBLE- BLINDED CONTROLLED TRIAL

EAQ222CD

Effectiveness of Out-of-Pocket Cost COMmunication and Financial Navigation (CostCOM) in Cancer Patients

CAMBRIA-2

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer

NRG-GU008

Testing the addition of the drug apalutamide to the usual hormone therapy and radiation therapy after surgery for prostate cancer

Author: Omotola Watkins